全球近視黃斑部病變市場：各地區及國家分析與預測（2025-2035）

由於高度近視盛行率上升、診斷和治療方案的進步以及人口老化等因素，全球近視黃斑部病變市場經歷顯著成長。

隨著近視性黃斑部病變治療和介入需求的不斷成長，該市場在改善視力喪失患者的治療效果和維持其生活品質方面發揮關鍵作用。該市場涵蓋診斷工具、治療技術（例如抗VEGF療法）以及管理視力喪失的輔助技術。

持續關注近視黃斑部病變的早期診斷、治療和併發症管理，對於滿足日益增加的近視患者的需求非常重要。認知度的提升、醫療基礎設施的改善以及治療方案的便利性，推動市場的成長。

在全球範圍內，尤其是在都市區，近視發病率的上升與近視性黃斑部病變風險的增加直接相關，也是市場的主要成長要素之一。除了近視整體呈上升趨勢外，高度近視的發生率也在上升。研究表明，高度近視患者數量的成長速度快於中度或輕度近視患者，預計到2050年，全球高度近視人口可能超過10億。這種成長與近視性黃斑部病變病例數量的增加直接相關。

此外，抗血管內皮生長因子（VEGF）療法的開發對近視黃斑部病變的治療前景產生重大影響。這些治療方法透過抑制視網膜內異常血管的生長來解決視力喪失的主要原因之一。新型抗 VEGF 療法和聯合治療的核准提高治療效果、改善治療可及性並改善患者預後。

儘管存在這些積極的成長趨勢，全球近視黃斑部病變市場仍面臨許多挑戰。主要挑戰之一是高昂的治療費用，這對許多患者，尤其是開發中國家和服務欠缺地區的患者，構成了巨大的醫療障礙。近視黃斑部病變病變治療費用高昂，包括藥物治療和手術治療，這往往使患者無法獲得所需的護理，阻礙了市場成長。此外，由於與其他疾病的預算競爭，醫療保健系統難以撥出足夠的資金來治療近視黃斑部病變。

隨著近視性黃斑部病變市場的不斷發展，預計將在未來幾年塑造市場動態的新興趨勢包括開發更具針對性和個性化的治療方法、利用數位健康技術進行早期發現和後續觀察，以及日益重視預防和患者教育。近視性黃斑部病變病變的盛行率不斷上升，尤其是在老齡化人口和高度近視盛行率高的地區，預計將推動對更容易獲得、更有效且更實惠的治療方法的需求。此外，對創新藥物、眼科給藥裝置開發和手術技術進步的投資不斷增加，可能在未來幾年為關鍵相關人員提供巨大的成長機會。

本報告調查了全球近視黃斑部病變市場，並總結了主要趨勢、影響市場的因素分析、法律制度、臨床試驗趨勢、市場規模趨勢和預測、各個細分市場、地區/主要國家的詳細分析、競爭格局和主要企業的概況。

目錄

執行摘要

第1章 市場：產業展望

• 市場趨勢
• 法律規範
• 近視黃斑部病變的流行病學
• 臨床試驗分析
• 市場動態
  • 影響分析
  • 市場促進因素
  • 市場挑戰
  • 市場機會

第2章 全球近視黃斑部病變市場（依地區）

• 北美洲
• 歐洲
• 亞太地區
  • 主要調查結果
  • 市場動態
  • 市場規模及預測

第3章 全球近視黃斑部病變市場：競爭格局與公司概況

• 關鍵發展和策略
  • M&A
  • 協同努力
  • 業務擴展和資金籌措
  • 產品發布和核准
  • 其他活動
• 公司簡介
  • Regeneron Pharmaceuticals Inc.
  • F. Hoffmann-La Roche Ltd
  • Bayer AG.

第4章 調查方法

Global Myopic Macular Degeneration Market, Analysis and Forecast: 2025-2035

The global myopic macular degeneration market is experiencing significant growth, primarily driven by the increasing prevalence of high myopia, advancements in diagnostic and therapeutic solutions, and a growing aging population. As demand for treatments and interventions for myopic macular degeneration rises, the market plays a crucial role in improving patient outcomes and maintaining the quality of life for individuals affected by vision impairment due to myopia-related complications. The myopic macular degeneration market encompasses diagnostic tools, therapeutic innovations like anti-VEGF therapies, and supportive technologies to manage vision loss.

The continued focus on early diagnosis, treatment, and managing complications from myopic macular degeneration is crucial in addressing the increasing number of individuals affected by this condition. Increased awareness, improved healthcare infrastructure, and enhanced accessibility to treatment options are fuelling the growth of this market.

One of the significant drivers of the global myopic macular degeneration market is the rising global incidence of myopia, particularly in urbanized regions, is directly contributes to a higher risk of developing myopic macular degeneration. Myopia in general is becoming more widespread, and the proportion of people developing high myopia is also on the rise. Research indicates that high myopia is growing more rapidly than moderate or low myopia, with estimates suggesting that the number of individuals with high myopia could increase to over 1 billion globally by 2050. This growing number directly correlates with a rise in myopic macular degeneration cases.

Moreover, the development of anti-vascular endothelial growth factor (VEGF) therapies has significantly impacted the treatment landscape for myopic macular degeneration. These therapies help in preventing the growth of abnormal blood vessels in the retina, addressing one of the key causes of vision loss in myopic macular degeneration. The approval of new anti-VEGF treatments and combination therapies enhances the effectiveness of interventions, making treatments more accessible and improving patient outcomes.

Despite the positive growth trajectory, several challenges continue to impact the global myopic macular degeneration market. One of the primary challenges is the high cost of treatments, which creates a barrier to accessibility for many patients, especially in developing countries or underserved regions. The high costs of both medication and surgeries related to myopic macular degeneration treatment can limit patient access, which in turn hampers the growth of the market. Healthcare systems are often challenged to allocate funds for myopic macular degeneration treatments, given the competitive pressures from other conditions that also demand funding.

Leading players in the global myopic macular degeneration market, such as Regeneron Pharmaceuticals Inc., F. Hoffmann-La Roche Ltd, and Bayer AG, are continuously innovating to improve the effectiveness and comfort of myopic macular degeneration products. These companies are investing heavily in research and development to introduce new, technologically advanced solutions that cater to market growth. With a strong emphasis on user-friendly and environmentally sustainable products, these companies are shaping the future of myopic macular degeneration while enhancing their market positions globally.

The competitive landscape of the global myopic macular degeneration market is diverse, with numerous players across different regions offering a wide range of products. Regional players and local manufacturers are expected to play an important role in the market's growth, especially as demand increases in emerging markets such as Asia-Pacific. As consumer preferences shift towards more discreet, comfortable, and affordable solutions, the myopic macular degeneration market will continue to evolve, fostering new opportunities for both established and emerging companies.

As the myopic macular degeneration (MMD) market continues to evolve, emerging trends such as the development of more targeted and personalized therapies, the increasing use of digital health technologies for early detection and monitoring, and the growing focus on prevention and patient education are expected to shape its future landscape. The rising prevalence of myopic macular degneration, especially in aging populations and regions with high myopia rates, will fuel demand for more accessible, effective, and affordable treatment options. Additionally, the increasing investment in innovative drug development, development of ophthalmic drug delivery devices, and surgical techniques will present significant growth opportunities for key stakeholders in the coming years.

In conclusion, the global myopic macular degeneration market is poised for steady growth, driven by advancements in treatment technologies, a growing awareness of the condition, and the ongoing efforts to enhance patient outcomes. As the need for specialized care increases, both global and regional players will continue to play a critical role in providing solutions to those affected by myopic macular degeneration, ultimately improving the quality of life for patients and ensuring better long-term eye health.

Table of Contents

Executive Summary

Scope and Definition

Market/Product Definition

Inclusion and Exclusion

Key Questions Answered

Analysis and Forecast Note

1. Markets: Industry Outlook

• 1.1 Introduction
• 1.2 Market Trends
• 1.3 Regulatory Framework
• 1.4 Epidemiology of Myopic Macular Degeneration
• 1.5 Clinical Trial Analysis
• 1.6 Market Dynamics
  • 1.6.1 Impact Analysis
  • 1.6.2 Market Drivers
  • 1.6.3 Market Challenges
  • 1.6.4 Market Opportunities

2. Global Myopic Macular Degeneration Market (Region), ($Million), 2023-2035

• 2.1 North America
  • 2.1.1 Key Findings
  • 2.1.2 Market Dynamics
  • 2.1.3 Market Sizing and Forecast
    • 2.1.3.1 North America Myopic Macular Degeneration Market, by Country
      • 2.1.3.1.1 U.S.
• 2.2 Europe
  • 2.2.1 Key Findings
  • 2.2.2 Market Dynamics
  • 2.2.3 Market Sizing and Forecast
    • 2.2.3.1 Europe Myopic Macular Degeneration Market, by Country
      • 2.2.3.1.1 Germany
      • 2.2.3.1.2 U.K.
      • 2.2.3.1.3 France
      • 2.2.3.1.4 Italy
      • 2.2.3.1.5 Spain
• 2.3 Asia Pacific
  • 2.3.1 Key Findings
  • 2.3.2 Market Dynamics
  • 2.3.3 Market Sizing and Forecast
    • 2.3.3.1 Asia Pacific Myopic Macular Degeneration Market, by Country
      • 2.3.3.1.1 Japan

3. Global Myopic Macular Degeneration Market: Competitive Landscape and Company Profiles

• 3.1 Key Development and Strategies
  • 3.1.1 Mergers and Acquisitions
  • 3.1.2 Synergistic Activities
  • 3.1.3 Business Expansions and Funding
  • 3.1.4 Product Launches and Approvals
  • 3.1.5 Other Activities
• 3.2 Company Profiles
  • 3.2.1 Regeneron Pharmaceuticals Inc.
    • 3.2.1.1 Overview
    • 3.2.1.2 Top Products / Product Portfolio
    • 3.2.1.3 Top Competitors
    • 3.2.1.4 Target Customers/End-Users
    • 3.2.1.5 Key Personnel
    • 3.2.1.6 Analyst View
  • 3.2.2 F. Hoffmann-La Roche Ltd
    • 3.2.2.1 Overview
    • 3.2.2.2 Top Products / Product Portfolio
    • 3.2.2.3 Top Competitors
    • 3.2.2.4 Target Customers/End-Users
    • 3.2.2.5 Key Personnel
    • 3.2.2.6 Analyst View
  • 3.2.3 Bayer AG.
    • 3.2.3.1 Overview
    • 3.2.3.2 Top Products / Product Portfolio
    • 3.2.3.3 Top Competitors
    • 3.2.3.4 Target Customers/End-Users
    • 3.2.3.5 Key Personnel
    • 3.2.3.6 Analyst View

4. Research Methodology

List of Figures

• Figure: Global Myopic Macular Degeneration Market, Dynamics Impact Analysis
• Figure: Epidemiology of Myopic Macular Degeneration
• Figure: Global Myopic Macular Degeneration Market Coverage
• Figure: Global Myopic Macular Degeneration Market Key Trends, Impact Analysis, 2023-2035
• Figure: Global Myopic Macular Degeneration Market, Competitive Landscape, January 2022-April 2025

List of Tables

• Table: Global Myopic Macular Degeneration Market, Clinical Trial Analysis,
• Table: Global Myopic Macular Degeneration Market Dynamics, Impact Analysis
• Table: Global Myopic Macular Degeneration Market (by Region), $Million, 2023-2035